Display options
Cite
Tang J, Lee Y, Ravichandran S, et al. Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. iScience. 2021;24(9):103006doi: 10.1016/j.isci.2021.103006.
Tang, J., Lee, Y., Ravichandran, S., Grubbs, G., Huang, C., Stauft, C. B., Wang, T., Golding, B., Golding, H., & Khurana, S. (2021). Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. iScience, 24(9), 103006. https://doi.org/10.1016/j.isci.2021.103006
Tang, Juanjie, et al. "Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern." iScience vol. 24,9 (2021): 103006. doi: https://doi.org/10.1016/j.isci.2021.103006
Tang J, Lee Y, Ravichandran S, Grubbs G, Huang C, Stauft CB, Wang T, Golding B, Golding H, Khurana S. Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. iScience. 2021 Sep 24;24(9):103006. doi: 10.1016/j.isci.2021.103006. Epub 2021 Aug 20. PMID: 34430803; PMCID: PMC8378063.
Copy Download .nbib Format: NLM
Share it on

iScience. 2021 Sep 24;24(9):103006. doi: 10.1016/j.isci.2021.103006. Epub 2021 Aug 20.

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern.

iScience

Juanjie Tang, Youri Lee, Supriya Ravichandran, Gabrielle Grubbs, Chang Huang, Charles B Stauft, Tony Wang, Basil Golding, Hana Golding, Surender Khurana

Affiliations

  1. Division of Viral Products, Office of Vaccines Research and Review, Silver Spring, MD 20993, USA.
  2. Division of Plasma Protein Therapeutics, Office of Tissues and Therapeutic Proteins, Center for Biologics Evaluation and Research, Food and Drug Administrationa (FDA), 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

PMID: 34430803 PMCID: PMC8378063 DOI: 10.1016/j.isci.2021.103006

Abstract

Hyperimmune immunoglobulin (hCoV-2IG) generated from SARS-CoV-2 convalescent plasma (CP) are under evaluation in clinical trials. Here we explored the antibody epitope repertoire, and virus neutralizing capacity of six hCoV-2IG batches as well as nine CP against SARS-CoV-2 and emerging variants of concern (VOCs). Epitope-mapping by gene-fragment phage display library spanning the SARS-CoV-2 spike demonstrated broad recognition of multiple antigenic sites spanning the entire spike that was higher for hCoV-2IG than CP, with predominant binding to the fusion peptide. In the pseudovirus neutralization assay and in the wild-type SARS-CoV-2 PRNT assay, hCoV-2IG lots showed higher titers against the WA-1 strain compared with CP. Neutralization of VOCs were reduced to different extent by hCoV-2IG lots but were higher than CP. Significant reduction of hCoV-2IG binding was observed to RBD-E484K followed by RBD-N501Y (but not RBD-K417N). This study suggests that post-exposure treatment with hCoV-2IG could be preferable to CP.

Keywords: biological sciences; immune response; immunology

Conflict of interest statement

The authors declare no competing interests.

References

  1. Cell Host Microbe. 2020 Feb 12;27(2):262-276.e4 - PubMed
  2. J Infect Dis. 2021 Sep 1;224(5):764-770 - PubMed
  3. Nat Med. 2021 Apr;27(4):622-625 - PubMed
  4. Sci Transl Med. 2020 Jul 1;12(550): - PubMed
  5. Transfusion. 2021 Jun;61(6):1705-1709 - PubMed
  6. Science. 2020 Sep 25;369(6511):1550-1551 - PubMed
  7. Science. 2020 Nov 27;370(6520): - PubMed
  8. Science. 2021 Jan 22;371(6527):329-330 - PubMed
  9. Science. 2020 Oct 23;370(6515): - PubMed
  10. Cell Rep. 2020 Oct 20;33(3):108274 - PubMed
  11. Nat Commun. 2021 Feb 22;12(1):1221 - PubMed
  12. PLoS One. 2021 Mar 10;16(3):e0248348 - PubMed
  13. Sci Adv. 2021 Mar 5;7(10): - PubMed
  14. JAMA. 2021 Apr 6;325(13):1261-1262 - PubMed
  15. J Exp Med. 2021 May 3;218(5): - PubMed
  16. J Infect Dis. 2021 Mar 3;223(5):743-751 - PubMed
  17. Lancet Respir Med. 2019 Nov;7(11):951-963 - PubMed
  18. Nature. 2021 Jul;595(7866):283-288 - PubMed
  19. Science. 2021 Jan 8;371(6525):108-109 - PubMed
  20. Cell. 2021 Apr 1;184(7):1821-1835.e16 - PubMed
  21. Nat Microbiol. 2020 Oct;5(10):1185-1191 - PubMed
  22. mBio. 2021 Mar 2;12(2): - PubMed
  23. Signal Transduct Target Ther. 2020 Aug 25;5(1):170 - PubMed
  24. PLoS Pathog. 2016 Apr 21;12(4):e1005554 - PubMed
  25. N Engl J Med. 2021 Mar 18;384(11):1015-1027 - PubMed
  26. Cell. 2020 May 28;181(5):1004-1015.e15 - PubMed
  27. Nature. 2021 Feb;590(7847):630-634 - PubMed
  28. NPJ Vaccines. 2018 Oct 1;3:40 - PubMed
  29. J Clin Invest. 2021 Apr 1;131(7): - PubMed
  30. Lancet Respir Med. 2021 Jul;9(7):712-720 - PubMed
  31. Cell. 2021 Apr 29;184(9):2348-2361.e6 - PubMed
  32. Science. 2021 Jan 1;371(6524):9-10 - PubMed
  33. PLoS Med. 2009 Apr 21;6(4):e1000049 - PubMed
  34. Cell. 2021 Mar 4;184(5):1201-1213.e14 - PubMed
  35. J Infect Dis. 2020 Feb 3;221(4):636-646 - PubMed
  36. Sci Transl Med. 2011 Jun 1;3(85):85ra48 - PubMed
  37. Expert Rev Clin Immunol. 2021 Apr;17(4):309-316 - PubMed
  38. N Engl J Med. 2021 Mar 17;384(15):1468-1470 - PubMed
  39. J Clin Invest. 2020 Oct 1;130(10):5112-5114 - PubMed
  40. Nature. 2021 May;593(7857):130-135 - PubMed
  41. Cell Rep. 2021 Feb 2;34(5):108699 - PubMed
  42. Science. 2021 Mar 26;371(6536):1306-1308 - PubMed
  43. Lancet. 2021 Mar 13;397(10278):952-954 - PubMed

Publication Types